Перегляд вихідного коду сторінки Which Kind Of ALOX15 I Really Wish To Have

Mesenteric-to-left portal vein bypass (Rex shunt) has been reported with good results in terms of feasibility, prevention of rebleeding, restoration of portal inflow and hepatic function and improvement [http://www.selleckchem.com/products/AZD0530.html selleck chemicals llc] in cognitive function. Other shunts with the splenic or mesenteric vein, when available, have achieved good results. Outcome may be mostly jeopardized by cholangiopathy and minimal chronic hepatic encephalopathy in patients whose recurrent bleeding is well controlled with endoscopic therapy. ""Watch a video presentation of this article Watch the interview with the author Answer questions and earn CME ALT alanine aminotransferase CHB chronic hepatitis B HBeAg hepatitis B e antigen HBsAg hepatitis B surface antigen HBV hepatitis B virus NA nucleos(t)ide analogue PEG-IFN pegylated interferon Although safe and effective vaccines have been available for several decades, chronic hepatitis B (CHB) remains one of the most prevalent infectious diseases. Therefore, many patients require antiviral therapy to prevent progression to cirrhosis, liver failure, hepatocellular carcinoma, and liver-related death.1 The potential of antiviral therapy for CHB has [http://en.wikipedia.org/wiki/ALOX15 ALOX15] increased enormously in recent years as a result of the introduction of pegylated interferon (PEG-IFN), which renewed the interest for this immunomodulating drug, as well as the introduction of better nucleos(t)ide analogues (NAs). Even though NAs are very effective, increasing evidence suggests that after hepatitis B e antigen (HBeAg) seroconversion, stopping NA therapy results in a relapse of hepatitis B virus (HBV) infection in the majority of patients.2 We therefore have to anticipate that NA should be given indefinitely. Thus, the long-term side effects and costs of NA should be taken into account when initiating such therapy. Both treatment modalities (NA and PEG-IFN) have proven to be effective, but current guidelines are lacking clear recommendations as to which treatment strategy should be used as first-line therapy.1 In HBeAg-positive patients, PEG-IFN results in a response (sustained HBeAg seroconversion 24 weeks posttreatment) in approximately 25% to 30% of patients. [http://www.selleckchem.com/products/wnt-c59-c59.html selleck compound] In HBeAg-negative patients, a sustained response (HBV DNA